Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis

Importance: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5-DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized. Objective: To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5-DM. Design, Setting, and Participants: This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5-DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures: Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures: Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index. Results: Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5-DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance: The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5-DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5-DM.

Authors

Institutions

Publication Details

Journal
JAMA Dermatology
Published
2026-11-18
DOI
https://doi.org/10.1001/jamadermatol.2026.4776
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis

Chen Zong, Yongpeng Ge, Longyang Zhu, Qinglin Peng et al.
3 links
JAMA Dermatology
Inflammatory Myopathies and Dermatomyositis
article

Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis

Chen Zong, Yongpeng Ge, Longyang Zhu, Qinglin Peng, Yiran Chen, Linrong He, Xiaoming Shu, Guochun Wang, Chunjia Li, Xiaolan Tian, Xinyue Xiao, Qi Pan, Lin Liang, Sizhao Li, Xia Liu, Xiaoqin Luo, Shanshan Li, Yunfeng Dai, Xin Lu, Wei Jiang, Lu Zhang, Fang Chen, Hanbo Yang, Lin Luo, Huihui Ji, Xinxin Zhang, ying li
article en

Abstract

Importance: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5-DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized. Objective: To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5-DM. Design, Setting, and Participants: This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5-DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures: Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures: Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index. Results: Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5-DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance: The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5-DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5-DM.

JAMA Dermatology
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), China-Japan Friendship Hospital (CN)
Good health and well-being
Inflammatory Myopathies and Dermatomyositis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon